argenx NV ADR (ARGX)vsHumacyte Inc (HUMA)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
HUMA
Humacyte Inc
$1.39
-4.14%
HEALTHCARE · Cap: $299.73M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 235142% more annual revenue ($4.74B vs $2.02M). ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
HUMA
Avoid14
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Margin of Safety
+55.3%
Fair Value
$2.26
Current Price
$1.39
$0.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 27.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : HUMA
HUMA has a balanced fundamental profile.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : HUMA
The primary concerns for HUMA are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 5.67 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARGX profiles as a growth stock while HUMA is a value play — different risk/reward profiles.
HUMA carries more volatility with a beta of 2.46 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 14/100), backed by strong 31.4% margins and 62.6% revenue growth. HUMA offers better value entry with a 55.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Humacyte Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Humacyte Inc (HUMA) is an innovative biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs) aimed at addressing critical clinical demands in vascular reconstruction and chronic disease management. By offering off-the-shelf solutions, Humacyte enhances patient outcomes while aiming to reduce overall healthcare expenditures. Leveraging its cutting-edge technology platform, the company is well-positioned to lead advancements in transplantation and tissue engineering, establishing itself as a key player in the rapidly evolving medical therapies sector.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?